Search      Advanced Search | Browse By Topic
Magazine Content
Home
Features
Columnists
Industry Risk Reports
In-Depth Series
Special Reports
Point/Counterpoint
R&I One® Content
News & Analysis
Editor's Choice Stories
Resources and Tools
Power Broker® Directory
Risk InnovatorTM
Emerging Risks
Top Employee Benefits Consultant
Executives To Watch
Insights
Industry Events
WorkersComp Forum
Award Nominations
Webinars
RSS
R&I Information
Subscription Center
Advertiser Information
About Us
Contact Us
 

Newsletter Sign-up

Click on the name of the free newsletter below to preview:

R&I One®
WORKERSCOMP Forum TM Update
HTML Text
E-Mail Address:


Click here to unsubscribe
Privacy Policy
Preferences

 

Pharmaceuticals 2012 Power Brokers



             2012 Power Broker® Winners
Edwin Albers
Director
Aon, Portland, Ore.

Knowledge is Power

Edwin Albers, director of the Aon Risk Solutions Life Sciences Group, could have acted like the rest of the brokers.

Working with a producer of nutraceuticals -- products like vitamins that provide health and medical benefits -- Albers could have simply resigned himself to the fact that the company would have to pay high premiums because their products aren't regulated by the Food and Drug Administration.

He could have accepted the fact that their products are seen as dangerous -- even though they have strict testing policies and their products do lots of good for people every day.

He could have accepted the fact that the ephedra scandal of the early 2000s is simply too much to overcome, so they should have just sat back and dealt with bad rates in a tainted industry.

He could have, but he didn't.

Instead, the Portland, Ore.-based Albers did plenty of research on the safety of the products and relayed that message to the carriers. Eventually, he got them to agree to consolidate all insurance policies for the nutraceutical company -- from general liability to property -- leading to a savings of $400,000 or about 17 percent, according to the company's assistant treasurer. His willingness to learn about the nutraceuticals products set him apart from the rest of the brokerage field.

"We feel it's critical and that's what we were looking for in selecting a new broker," he said. "We feel like we're doing things the right way. We're doing things better than most of the people in the category we're put into. We feel like we're very different than the companies we get lumped in with."

Albers also proved to be a big help for Opto Circuits, a medical device and technology company.

After an acquisition, Albers developed a plan to consolidate the company's insurance, saving $1 million in just one year, said Manesh Patel, the company's chief financial officer.

"We like Eddie's ideas," said Patel. "Now our insurance is easier to manage. We've got one policy dealing with one agent and one insurance company."

Timothy Gosnear, CPCU
Managing Director
Aon, Philadelphia

Broker Reassures Carriers

Enzyme replacement drugs can have wide ranging impacts that have been wonder drugs for patients with rare lysosomal disorders like Gaucher disease, Fabry disease, Pompe disease and Mucopolysaccharidosis. Genzyme, a Cambridge Mass.-based company offers enzyme-replacement treatments to fight those inherited ailments, as well as marketing others for more common illnesses like chronic kidney disease and leukemia.

With a market so narrow and virtually unknown to the general public, every renewal is an adventure.

But when you've got someone on your side like Timothy Gosnear, managing director and strategic account manager of the life sciences practice at Aon Risk Solutions, things tend to go much more smoothly than expected. His industry knowledge and ability to relay safety information to carriers sets him apart.

"It's a very narrow market. It's a really high risk and the losses are pretty significant," said Ron Kaufman, senior director of risk management at Genzyme who explained that the "success rate is very high" and testing is very rigorous. But try explaining that to an insurance carrier whose only understanding of Genzyme products is that they are headed for cancer patients and people on kidney dialysis. The risks just seem too high.

That's where Gosnear comes in. When working with the insurance carriers, he's been able to emphasize the safety and curative powers of Genzyme's products. As a result he has consistently been able to keep insurance prices affordable for his client companies.

"We had a successful renewal in June," said Kaufman. "We got all the coverage we need and stayed within budget." Gosnear's not just a Power BrokerŪ for small companies with specific risks, he's also valuable to larger players. For a major pharmaceutical company, Gosnear has become such an asset that the company's director of risk management calls him "an extension of my internal staff."

She even says that she'll "go down the hall and ask questions to employees," she said. "I'll do the same to him. There's a seamless connection with our risk management team."

Ty Howe, ARM
Senior Vice President
Marsh, Boston

A Fast Mover

Some attributes set Power BrokersŪ apart from the rest -- responsiveness, knowledge and creativity come to mind. But Ty Howe, senior vice president of Marsh Inc. in Boston, adds one more to the mix: speed.

When Coronado Biosciences, a small biopharmaceutical company, went public in 2011, the business was under the gun to change from a private directors' and officers' policy to a public one.

The company focuses on immunotherapy agents for cancer and inflammatory diseases such as acute myeloid leukemia, inflammatory bowel disease and multiple sclerosis.

With a window of only 60 days, Dale Ritter, Coronado's senior vice president of finance, could only think of one broker for the job: Ty Howe.
v "There really was no question in my mind who I was going to call," said Ritter who's dealt with Howe since the early 1990s. "He caused the wheels to turn and we got our policy in place in time."

Despite the narrow window, Howe did his due diligence to get plenty of offers from carriers.

In the end, Coronado got quality coverage as well as competitive benchmarks. With his help, Coronado can now face the future as a public company.

"One of the things I put a lot of emphasis on is responsiveness," said Ritter. "Ty and his team get back to you right away when you have a need."

Howe also filled a gap in the market for physicians. Since pharmaceutical companies aren't allowed to refund doctors for lost or mishandled drugs due to anti-kickback laws, Howe created an insurance policy allowing physicians to submit claims for lost drugs on a dedicated website. The limit is set at $15,000 per year.

If that weren't enough, he negotiated coverage for microbial contamination of a production facility.

Previously, property insurance policies only responded to contamination if it followed a physical damage loss due to a covered peril, even though microbial contamination could do serious damage.

The coverage trigger was typically from an Environmental Protection Agency regulated event, but through his work, it will now include Food and Drug Administration regulated events.

Dirk Van Heyst
Senior Vice President
Lockton, New York

Broker Acts as Insurance Supplement

Dietary supplement companies seem to be in a constant pickle: they're trying to offer products that help people get the most out of their exercises, lose weight or live healthier lives.

At the same time, it's hard to secure insurance because their products aren't approved by the Food and Drug Administration.

Not to mention the industry is still feeling the pain of the 2004 ephedra scandal when the FDA banned the substance a year after a medical examiner said ephedra played a "significant role" in the heart attack death of Baltimore Orioles pitcher Steve Belcher.

With that backdrop, broker Dirk Van Heyst, senior vice president at Lockton, went to work trying to place insurance for a dietary supplement company. Then came another wrinkle: one of the large retailers that purchases supplements from the company required the supplement manufacturer to carry 40 percent more insurance.

"We don't send Dirk to market with a royal flush or a perfect hand to play," said the company's general counsel. "But we are a good company. Quality is very important to us. We have not had a claims history at all."

When working with the carriers, Van Heyst was able to emphasize the company's stringent testing policies as well as its sparse claims history. The result was a two-fold increase in coverage while premiums remained flat. Not bad in an industry that's tougher than most.

Van Heyst's industry knowledge does not just extend to the world of pharmaceuticals. He's also been extremely valuable to a wine-and-spirits company. So much so, in fact, that he seems like part of the staff.

The company's director of audit freely admits that he was an insurance newbie and relied heavily on Van Heyst.

"I explained to them the most I did in insurance was going to Geico to save 15 percent," he joked.

But with Van Heyst's help, he was able to reassess risk, saving money and time.

"I was spending 25 percent of my time on insurance. Now I only spend 5 percent to 10 percent," said the company's director of audit. "Now, I can focus on audit and risk management of my company."
 
«Return to the 2012 Power Broker® Page

 
 
 
 
 
 
 
 
 
 
 
RISK logo
 

Back to top

Entire contents copyright © 2013 Risk and Insurance® All rights reserved. May not be reproduced in any form without written permission.